Effect of Clinical Pharmacist Interventions on Prevention of Adverse Drug Events in Surgical Intensive Care Unit

Background: A pharmacist’s participation in medical rounds in intensive care unit (ICU) is becoming popular nowadays. In this study, we investigated the effect of pharmacologic intervention by a pharmacist’s participation in medical round in ICU on prevention of adverse drug events (ADEs). Methods: From March 2011 to July 2011, the intervention data were obtained by participating in medical round two or three times a week, and by reviewing electronic medical records of patients admitted to surgical ICU. The incidence, cause, and type of ADEs were noted, respectively. Expected cost avoidance was calculated from interventions, which were considered to be preventive of ADEs. The acceptance rate of pharmacologic interventions was noted. Results: Among 2781 patients, a total of 159 intervention data were collected in 90 patients. Recommendation for drug dosage adjustment or monitoring in patients with potential overdose and sub-therapeutic dose made up 82% of the total interventions. In 8% of interventions, initiation of drug therapy was recommended. 83% of the interventions were accepted and the acceptance rate of interventions within 24 hrs was 58%. The rate of the interventions, which were considered to be preventive of ADEs was 62%. Expected cost reduction obtained by preventing ADEs was 25,867,083₩ during a 5-month period. Conclusions: A pharmacist’s participation in physician rounds in ICU was associated with prevention of ADEs and subsequent reduction of the cost in drug therapy.

[1]  M. Hiesmayr Nutrition risk assessment in the ICU , 2012, Current opinion in clinical nutrition and metabolic care.

[2]  J. Rothschild,et al.  Analysis of risk factors for adverse drug events in critically ill patients* , 2012, Critical care medicine.

[3]  M. Boermeester,et al.  Cost-effectiveness of ward-based pharmacy care in surgical patients: protocol of the SUREPILL (Surgery & Pharmacy In Liaison) study , 2011, BMC health services research.

[4]  Susanne M. Smorenburg,et al.  On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study , 2010, Critical care.

[5]  L. Køber,et al.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.

[6]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  R. Henkin,et al.  An Open-Label Controlled Trial of Theophylline for Treatment of Patients With Hyposmia , 2009, The American journal of the medical sciences.

[8]  Michael D Howell,et al.  Acid-suppressive medication use and the risk for hospital-acquired pneumonia. , 2009, JAMA.

[9]  C. A. Bond,et al.  Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections* , 2008, Critical care medicine.

[10]  B. Erstad,et al.  Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  Joan Costa,et al.  Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom , 2007, Therapeutics and clinical risk management.

[12]  S. Kane-Gill,et al.  Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  Imad F. Btaiche,et al.  Metabolic complications of parenteral nutrition in adults, Part 2. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[14]  Michael J Dooley,et al.  A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. , 2004, British journal of clinical pharmacology.

[15]  M. Postma,et al.  Impact of pharmacist recommendations on the cost of drug therapy in icu patients at a Malaysian hospital , 2003, Pharmacy World and Science.

[16]  G. V. Berghe,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[17]  D. A. White,et al.  Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  D. Bates,et al.  Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. , 1999, JAMA.

[19]  A. Levin,et al.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Boeckh,et al.  Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. , 1997, Blood.

[21]  D. Bates,et al.  Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.

[22]  A. Mutnick,et al.  Cost savings and avoidance from clinical interventions. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  E. Goldstein,et al.  Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Dagan,et al.  Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group , 1995, Antimicrobial agents and chemotherapy.

[25]  A. Keren,et al.  Suppression of ventricular arrhythmias by magnesium. , 1990, The American journal of cardiology.

[26]  C. Neumann,et al.  Safety of intravenous ciprofloxacin. A review. , 1989, The American journal of medicine.

[27]  B. Katona,et al.  Effect of a pharmacist's and a nurse's interventions on cost of drug therapy in a medical intensive-care unit. , 1989, American journal of hospital pharmacy.

[28]  A. Shields,et al.  THE USE OF RANITIDINE IN BONE MARROW TRANSPLANTATION: A Review Of 223 Cases , 1988, Transplantation.

[29]  G. Calandra,et al.  The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. , 1986, The Journal of antimicrobial chemotherapy.

[30]  S. Lerner,et al.  Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. , 1986, The American journal of medicine.

[31]  J. Tredger,et al.  Hepatotoxicity to sodium valproate: a review. , 1984, Gut.

[32]  J. Gatell,et al.  Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin , 1983, Antimicrobial Agents and Chemotherapy.

[33]  C. R. Smith Cefotaxime and cephalosporins: adverse reactions in perspective. , 1982, Reviews of infectious diseases.

[34]  E. Antman,et al.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. , 1980, The New England journal of medicine.

[35]  H. Ikeuchi,et al.  Evaluation of teicoplanin dosing designs to achieve a new target trough concentration , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[36]  D. Richards,et al.  Cefotetan , 2012, Drugs.

[37]  G. Eliopoulos,et al.  The Sanford guide to antimicrobial therapy , 2010 .

[38]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[39]  D. Kelly Liver complications of pediatric parenteral nutrition--epidemiology. , 1998, Nutrition.

[40]  Mchardy Gg A multicenter, double-blind trial of sucralfate and placebo in duodenal ulcer. , 1981 .

[41]  G. McHardy A multicenter, double-blind trial of sucralfate and placebo in duodenal ulcer. , 1981, Journal of clinical gastroenterology.